[Clinical analysis of 132 cases of cervical adenosquamous carcinoma and cervical adenocarcinoma].
OBJECTIVE
The incidence of cervical adenosquamous carcinoma is relatively low. This study was to analyze the clinicopathologic characteristics and prognostic factors of cervical adenosquamous carcinoma.


METHODS
Clinical data of 44 cervical adenosquamous carcinoma patients and 88 cervical adenocarcinoma patients(control), treated from January 2002 to December 2007, were analyzed using Chi-square test, Kaplan-Meier method, log-rank test, and Cox regression model.


RESULTS
The proportion of large tumors (maximal diameter > 4 cm) was significantly higher in cervical adenosquamous carcinoma group than in cervical adenocarcinoma group (47.7% vs. 28.4%, P<0.05); the proportion of poorly differentiated tumors was significantly higher in cervical adenosquamous carcinoma group than in cervical adenocarcinoma group (56.8% vs. 30.7%, P<0.05). Univariate analysis showed that tumor size (P=0.011), FIGO stage (P=0.013), depth of stromal invasion (P=0.05) and lymph node metastasis (P=0.017) were correlated with prognosis, while multivariate analysis showed that FIGO stage and lymph node metastasis had great impact on prognosis. There was no significant difference of 2-year overall and disease-free survival rates between the two groups (P>0.05).


CONCLUSIONS
Cervical adenosquamous carcinoma is characterized by large tumor size and poor differentiation. FIGO stage and lymph node metastasis are significant prognostic factors. There is no difference in prognosis between cervical adenosquamous carcinoma and cervical adenocarcinoma.
Meng
Yu-Han
YH
Department of Obstetrics and Gynecology, Huazhong University of Science and Technology,Wuhan, Hubei 430030, People's Republic of China.
Li
Shuang
S
Hu
Ting
T
Ma
Ding
D
Lu
Yun-Ping
YP
Wang
Hui
H
D000230:Adenocarcinoma / Q000473:pathology* / Q000556:secondary / Q000601:surgery / Q000628:therapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D018196:Carcinoma, Adenosquamous / Q000473:pathology* / Q000556:secondary / Q000601:surgery / Q000628:therapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000556:secondary; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010386:Pelvic Neoplasms / Q000556:secondary; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D015996:Survival Rate; D047368:Tumor Burden; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000601:surgery / Q000628:therapy